Compare Crispr Therapeutics AG (CRSP) vs iShares MSCI Japan ETF (EWJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs iShares MSCI Japan ETF — how do they compare? Crispr Therapeutics AG trades at $53.39 (market cap $4.88B), while iShares MSCI Japan ETF trades at $97.86 (market cap $23.87B). The key difference: iShares MSCI Japan ETF is far larger — about 4.9× Crispr Therapeutics AG's market cap, and iShares MSCI Japan ETF is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and iShares MSCI Japan ETF for 56 Days on average.
| CRSP | EWJ | |
|---|---|---|
Market Cap | $4.88B | $23.87B |
Volume | 2,861,747 | 5,412,820 |
Sector | Health | Broad Market / Factor |
52-Week High | $73.97 | $99.32 |
52-Week Low | $44.34 | $78.36 |
Typical Hold Time | 77 Days | 56 Days |
Enterprise Value | $3.30B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $50.44, down 3.65% on the day, reflecting a bearish technical trend amid weak financials. The company reported no revenue in 2025, with a net loss of $581.60M and negative profit margins, though it beat Q2 2026 EPS estimates. Analyst consensus remains bullish with a $67.83 price target, while recent news highlights upcoming clinical data readouts for its gene-editing therapies as potential catalysts.
The outlook hinges on pipeline execution, with key data expected by end-2026, but high cash burn and lack of revenue pose significant risks. Upside depends on successful clinical outcomes and commercialization of CASGEVY, while downside risks include trial failures and sustained losses.
EWJ, the iShares MSCI Japan ETF, trades at $97.32, down 1.02% over the past day amid broader Asian market volatility. Technical indicators are mixed, with a neutral overall signal and bullish moving averages, while key support sits at $96. Recent news highlights Japan's monetary policy shifts, including BOJ rate hikes and yen fluctuations, influencing ETF performance as international equities show strength relative to the S&P 500.
The outlook for EWJ hinges on Japan's economic trajectory and central bank actions, with potential upside from continued international equity outperformance. Risks include rising bond yields, fiscal uncertainties, and currency volatility, warranting caution for investors seeking exposure to Japanese markets through this ETF.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About iShares MSCI Japan ETF
EWJ tracks the MSCI Japan Index, providing broad exposure to over 180 large and mid-cap companies in Japan. It is the most established and liquid vehicle for accessing the Japanese equity market, featuring a diversified portfolio across industrials, consumer discretionary, and financial sectors.
Read more on EWJ →
